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Abstract
Introduction Faecal blood loss has been measured using
autologous erythrocytes labelled with radioactive chromium for
several decades, using generally similar methods. We
conducted a systematic review of studies employing this
technology to determine the degree of blood loss associated
with use of aspirin, nonsteroidal anti-inflammatory drugs
(NSAIDs) and cyclo-oxygenase-2 selective inhibitors (coxibs).
Methods A systematic search of PubMed and the Cochrane
Library (to December 2006) was conducted to identify
randomized trials in which treatment with aspirin, NSAIDs, or
coxibs was continued for at least 7 days, and with at least 7 days
of washout for crossover trials. Rates of faecal blood loss
associated with these agents were determined in the
randomized trials identified. Comparators were placebo, active,
or no treatment. Outcomes of interest were mean daily faecal
blood loss, and the number or proportion of individuals
recording faecal blood above 5 ml/day and above 10 ml/day.
Results Forty-five reports of 47 trials were included, including
1,162 individuals, mostly healthy volunteers and predominantly
young men. Only 136 patients (as opposed to healthy
volunteers; 12%) were included, and these were mostly older
people with an arthritic condition. Most NSAIDs and low-dose
(325 mg) aspirin resulted in a small average increase in faecal
blood loss of 1 to 2 ml/day from about 0.5 ml/day at baseline.
Aspirin at full anti-inflammatory doses resulted in much higher
average levels of blood loss of about 5 ml/day. Some individuals
lost much more blood than average, at least for some of the time,
with 5% of those taking NSAIDs having daily blood loss of 5 ml
or more and 1% having daily blood loss of 10 ml or more; rates
of daily blood loss of 5 ml/day or 10 ml/day were 31% and 10%,
respectively, for aspirin at daily doses of 1,800 mg or greater.
Conclusion At baseline, or with placebo, faecal blood loss is
measured at 1 ml/day or below. With low-dose aspirin and some
NSAIDs, average values may be two to four times this, and anti-
inflammatory doses of aspirin result in much higher average
losses. A small proportion of individuals respond to aspirin or
NSAIDs with much higher faecal blood loss of above 5 ml/day
or 10 ml/day. There are significant limitations regarding the
quality and validity of reporting of these studies, such as limited
size and inclusion of inappropriate participants. The potential for
blood loss and consequent anaemia requires more study.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective
analgesics and anti-inflammatory drug therapy is an important
pharmacological approach to treating various forms of pain,
chronic musculoskeletal pain in particular. NSAIDs have a
number of known adverse effects. NSAIDs (and aspirin) are
associated with upper gastrointestinal injury [1], acute renal
failure [2,3] and congestive heart failure [4,5]. Less well docu-
mented adverse events include associations with increased
fracture rates [6] and lower gastrointestinal injury [7-9]. The
latter includes bleeding [10-16] and permeability changes
[17-19]. Cyclo-oxygenase-2 selective inhibitors (coxibs) are
differentiated from traditional NSAIDs by lower rates of upper
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and lower gastrointestinal harm, and possibly by lack of effect
on bone.
The gastrointestinal outcomes most often reported in modern,
large, randomized trials and observational studies are upper
gastrointestinal bleeding [20-22] or hospital admission for
upper gastrointestinal bleeding [23-26]. Both outcomes rep-
resent a serious and significant clinical event that is probably
at one extreme of a spectrum of blood loss. Much less is
known about lower gastrointestinal bleeding and low-level
chronic blood loss. Measurements of blood loss to the entire
bowel demonstrate large differences between individuals, with
some individuals losing significant amounts of blood on a daily
basis, up to 50 ml or more [27,28].
The clinical significance of low-level blood loss is unclear. Mor-
ris and colleagues [29] found small bowel lesions in 10 out of
15 patients with both rheumatoid arthritis and anaemia. In ran-
domized trials anaemia was less common when patients were
treated with celecoxib rather than NSAIDs [30], and there was
lower rate of bowel injury with coxibs [14].
Various methods have been used to measure blood loss from
the whole bowel [18,31-33]. The use of radioactively labelled
autologous erythrocytes with concomitant measurement of
radioactivity in blood and faeces has been longest used. The
method involves stool collection for a number of days after
injection of 51Cr-erythrocytes. Methodological problems, nota-
bly those involving patients with long transit times [34], collec-
tion of all stool samples, avoidance of interfering behaviours
and suitable methods for measuring radioactivity in blood and
stool, were identified early on. Many randomized trials have
been conducted over a number of decades using essentially
similar methods. Typically, they compared the effects of aspi-
rin, NSAID, or coxib on mean daily faecal blood loss, with com-
parators of placebo or aspirin. We chose to examine these
trials systematically, both for effects on mean daily blood loss
across groups and to identify individuals with greater levels of
blood loss that might be connected with anaemia.
Materials and methods
Quality of Reporting of Meta-analyses guidelines were fol-
lowed where appropriate [35]. PubMed and the Cochrane
Library were searched to identify randomized trials using the
autologous radioactive chromium method to measure faecal
blood loss with aspirin, NSAIDs, or coxibs. The date of the last
search was December 2006. A series of free text terms was
used, using combinations of words in title and abstract, includ-
ing faecal (or fecal) blood loss, occult blood loss, chromium,
erythrocyte*, aspirin, N-acetylsalicylic acid, NSAID, nonsteroi-
dal anti-inflammatory drug, cyclooxygenase-2 inhibitor, as well
as the individual names of common drugs, including ibuprofen,
diclofenac, naproxen, indomethacin, ketoprofen, rofecoxib,
celecoxib, etoricoxib, valdecoxib and lumiracoxib. Electronic
searches were supplemented by exploration of bibliographies
of all papers obtained, and reviews of gastrointestinal damage
caused by aspirin or NSAIDs. Trials identified as possibly rel-
evant from title or abstract were obtained in full paper version.
Trials were included if they were randomized; if they used
chromium-labelled autologous erythrocytes to measure faecal
blood loss with collections in controlled conditions; if they had
at least one placebo arm in the trial; if they involved administra-
tion of any dose of aspirin, NSAID, or coxib for at least 7 days;
and if they were parallel group or had a crossover design with
at least 7 days of washout between therapies.
Information from each trial was abstracted into a table. Rele-
vant information concerned randomization, blinding, and with-
drawal and dropouts was collected to assess reporting quality
using a commonly used 5-point scoring system [36]. Method-
ological items noted were as follows: whether a history was
taken to exclude possible pre-existing causes of intestinal
bleeding; whether participants had a regular bowel habit;
dependence of inclusion on either a negative faecal occult
blood test or a measured low faecal blood loss on baseline
screening; whether the study was conducted on an inpatient
basis in controlled conditions; and how the method of calcu-
lating faecal blood loss was reported.
Other information noted included information on study design,
participants (age, sex, volunteer or patient), treatments (includ-
ing dose), duration, baseline faecal blood loss and daily faecal
blood loss at the longest time period. As well as noting mean
or median blood loss, we sought information about the number
of participants with faecal blood loss of greater than 5 ml/day
or greater than 10 ml/day.
It was recognized that trials would be heterogeneous in rela-
tion to active therapies used, including drug dose. The inten-
tion was to calculate weighted mean faecal blood loss using
results from individual treatment arms reporting mean or
median results, with weighting by number of participants in the
study group. It was expected that dispersion information
(standard deviation or standard error of the mean) would be
irregularly reported. In addition, the proportion of participants
with faecal blood loss above 5 ml/day or above 10 ml/day was
calculated.
It was expected that for aspirin the dose range might be large,
with studies using full-dose aspirin (arbitrarily set at ≥1,800
mg/day) or low-dose aspirin (arbitrarily set at ≤325 mg/day).
Results within these two dose ranges would be calculated
separately. For NSAIDs and coxibs, no extreme variation in
dose was envisaged, but the analysis plan allowed for exclu-
sion of very high or very low doses if these were outside the
usual daily dose range (for example, ibuprofen 800 to 2,400
mg/day, diclofenac 50 to 150 mg/day and naproxen 500 to
1,000 mg/day). The analysis plan also allowed for comparison
of results from healthy volunteers and patients. No otherAvailable online http://arthritis-research.com/content/10/1/R7
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sensitivity analyses were planned, and no statistical testing
was done.
Results
Figure 1 is a flow chart showing the choice of studies for inclu-
sion. Of papers examined in detail, 43 did not involve chro-
mium-labelled erythrocytes, were not randomized trials, or
were reviews, and six appeared to be possible randomized tri-
als but they did not include a drug under investigation. Ten ran-
domized trials did involve both chromium-labelled autologous
erythrocytes and a drug under review, but their duration was
less than 7 days (seven trials), had no information for the first
phase only of a crossover trial (two), had no washout between
treatments in a crossover study (one), or included only eight
participants in different trials, with data available on four for any
treatment (one).
There remained 45 reports of 47 randomized trials (Additional
file 1 includes details of the trials, including trial design; nature
of participants, and their sex, age and any illness; faecal blood
loss results; and references). Two reports [37,38] included
extractable information on two randomized trials, and one [28]
had additional information and analysis of two randomized tri-
als [39,40]. The trials had been published over 40 years (Table
1); 26 were described as double blind, and 25 had quality
scores of 3 or more out of 5 (Table 1). Thirty-four trials
reported therapy periods of 1 week (22 trials) or 2 weeks (12
trials), published mainly before the mid-1980s; 13 trials
reported therapy periods of 3 weeks (two trials) or 4 weeks or
longer (10 trials), published mainly since the mid-1980s.
A number of methodological criteria might reflect on the valid-
ity of a trial. For example, only 36 out of 47 trials indicated that
patients had been screened to exclude a pre-existing history
that might contribute to increased faecal blood loss, such as a
prior history of gastrointestinal disease or surgery; oral, nasal,
or rectal bleeding (including bleeding gums on brushing
them); or haemorrhoids. Almost all trials excluded current or
recent use of drugs that are likely to interfere with measure-
ments; typically, these were analgesics or low-dose aspirin,
and recent prior use of aspirin, NSAIDs, antacids, histamine
antagonists, or proton pump inhibitors. Behavioural issues
leading to exclusion were excessive alcohol use, excessive
use of caffeinated beverages, or peculiarities of diet. Only 12
trials used a negative faecal occult blood test as an entry cri-
terion, and only five used a baseline low daily faecal blood loss
to exclude participants. Regular bowel habit was an entry cri-
terion in 11 trials, whereas only five trials used controlled con-
ditions (inpatient or dormitory accommodation). Detailed
reporting of the method of measuring faecal and blood radio-
activity was uncommon, and although most reported at least a
reference four trials had neither details nor reference. Only two
trials [39,40] reported adequately on all of these points.
Almost all studies involved a baseline, pretreatment faecal
blood loss measurement over a period of days, and elevated
baseline faecal blood loss was also a reason for exclusion (and
occasionally investigation). The total number of individuals
investigated was 1,162. Most were healthy volunteers, pre-
dominantly young men; only 136 (12%) were patients, usually
older with an arthritic condition.
Table 2 shows the weighted mean daily faecal blood loss for
baseline measurements before treatment, on placebo and for
each treatment. For aspirin, data are divided according to
dose, with trials examining low-dose aspirin (all 325 mg/day)
or full-dose aspirin (≥1,800 mg/day). Daily mean faecal blood
loss for individual study arms is shown in Figure 2 for baseline,
placebo, coxibs and NSAIDs with at least two trials and 25
patients.
Most information on mean daily faecal blood loss was available
for baseline, the initial period before randomization and the
start of the trial proper. This was available in 38 trial arms and
950 participants. Baseline mean daily faecal blood loss was
below 1 ml/day in all but one study [41], in which it was 1.0
ml/day; the weighted mean was 0.46 ml/day. A somewhat
higher mean daily faecal blood loss of 0.76 ml/day was meas-
ured with placebo in 172 participants (Table 2).
Mean daily faecal blood loss was available for low-dose and
full-dose aspirin, 25 different NSAIDs, and rofecoxib and etor-
icoxib. There was information on 361 participants for aspirin at
doses greater than 1,800 mg/day, but for other aspirin doses,
NSAIDs and coxibs there was information on fewer than 100
participants, and mostly fewer than 50 participants. For 16
NSAIDs information available was on 20 individuals or fewer
(Table 2).
Figure 1
Flow diagram for study selection Flow diagram for study selection. RCT, randomized controlled trial.Arthritis Research & Therapy    Vol 10 No 1    Moore et al.
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For aspirin there appeared to be a dose-response relation (Fig-
ure 3), with maximum weighted mean values of up to 4 ml/day
at 2,000 mg/day, 6 ml/day at 3,000 mg/day, and 10 ml/day at
4,000 mg/day. The most commonly used NSAIDs had mean
daily faecal blood loss values of between 1 and 2 ml/day (ibu-
profen and naproxen 2.0 mL/day), apart from diclofenac, mel-
oxicam and etodolac, with values of about 0.5 to 0.9 ml/day
(Table 2 and Figure 2). Rofecoxib and etoricoxib also had low
mean daily faecal blood loss of 0.8 and 0.9 ml/day.
At baseline there was no obvious difference between healthy
young volunteers (0.44 ml/day, 835 individuals) and patients
(0.56 ml/day, 103 individuals). With aspirin at doses above
1,800 mg/day, the mean daily faecal blood loss was about
twice as high with volunteers (5.8 ml/day, 249 individuals) as
with patients (3.2 ml/day, 112 individuals).
A number of the studies either gave information on individual
patients or provided suitable information to identify whether
any participants individually had daily faecal blood loss above
5 or 10 ml/day. For instance, a range of individual mean values
was often provided. Such information permitted determination
that all patients had faecal blood loss of under than 5 and 10
ml/day if the upper value of the range was below 5 ml/day, but
if the top of the range was above 10 mL/day then this identified
only one such individual; others who may have had higher val-
ues could not be identified by this method, which therefore
provides a minimum estimate.
The estimated number and percentage of patients who individ-
ually had higher blood loss is shown in Table 3. Blood loss
greater than 5 ml/day did not occur with placebo in any partic-
ipant. For aspirin at 1,800 mg/day or more, 31% of partici-
pants had blood loss of 5 ml/day or greater, and 10% had loss
of 10 ml/day or greater. Lower rates of 5% and 1%, respec-
tively, were found for all NSAIDs combined.
Discussion
Systematic reviews have several utilities. They can shed new
light on a topic or resolve a difference of opinion, but some-
times they can indicate only what is in the literature, without
extensive analysis. For any analysis to make sense, it must be
based on information that is of sufficient quality to avoid bias,
it must be valid (at least within a reasonable definition for a
topic), and the volume of data analyzed must be of sufficient
size to prevent conclusions from being wafted about on the
winds of chance.
Systematic reviews can only attempt to make sense of the
information presented. In the case of the present review, the
number of trials of sufficient quality limited, increasing the like-
lihood of bias. We have defined validity, inter alia, by duration
of therapy at a minimum of 1 week and washouts of 1 week in
crossover studies. Analysis is limited by clinical factors, design
and reporting heterogeneity. There were only 1,162 partici-
pants in 47 trials (average 25/trial, split between several
groups in the parallel group trials). There were different levels
of reporting quality, both crossover and parallel designs, dura-
tion periods of 1 to 4 weeks, and 30 different treatments
(including placebo, and some at different doses); the bulk of
studies were conducted in young healthy men, but some were
conducted in young healthy women, and a minority (12%)
evaluated older patients. Other variables include whether
studies maintained participants in a controlled environment to
collect stool samples reliably, and the mechanics of measuring
radioactivity in stool samples. In the face of so many variables,
our judgement was that no statistical approach could possibly
be justified. Although we would like to know how any of these
variables might have affected the results, we cannot see how
such an analysis may be achieved and so we resorted to a
descriptive analysis.
Given the clear limitations of quality and validity in these indi-
vidually small trials, even a descriptive analysis can only be
undertaken with circumspection. Comment is, however, still
required on the results that are available.
In these randomized trials, conducted over five decades, some
(but not all) of the drugs investigated resulted in a small aver-
age increase in faecal blood loss of 1 to 2 ml/day. Aspirin
Table 1
Trial quality by decade of publication
Decade Quality score Total
12345
1960s 22
1970s 5 3 1 9
1 9 8 0 s 11 1 5722 6
1990s 5 3 8
2000s 1 1 2
T o t a l 12 1 61 5 44 7Available online http://arthritis-research.com/content/10/1/R7
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appeared to be associated with increased faecal blood loss in
a dose-dependent manner; full anti-inflammatory doses
(>1,800 mg/day) resulted in much higher average levels of
blood loss of about 5 ml/day, although even 325 mg/day
resulted in daily faecal blood loss equivalent to that with stand-
ard dose NSAIDs. For aspirin and NSAIDs, some individuals
lost much more blood on average, with 5% of those taking
NSAIDs having daily blood loss of 5 ml or more and 1% having
daily blood loss of 10 ml or more. Individual daily blood loss
above 50 ml was reported in some healthy young men with
ibuprofen [28], and with aspirin over as few as 5 days [32],
and individual rather high blood loss was reported
sporadically.
Table 2
Weighted mean daily faecal blood loss by therapy
Treatment/drug Studies or study arms (n)P a r t i c i p a n t s  ( n) Weighted mean faecal blood loss (ml/day)
Initial blood loss at start of trial 38 950 0.46
Placebo arm of treatment 14 172 0.76
Aspirin (>1,800 mg/day) 29 361 5.01
Aspirin (325 mg/day) 4 64 1.61
Ibuprofen 4 66 2.03
Fenoprofen 4 62 1.86
Piroxicam 6 60 1.89
Naproxen 4 59 1.98
Indomethacin 6 58 1.39
Etodolac 4 39 0.55
Rofecoxib 1 37 0.80
Diflusinal 4 33 1.68
Ketoprofen 3 28 1.42
Meloxicam 1 26 0.85
Etoricoxib 1 21 0.90
Diclofenac 1 21 0.50
Azapropazone 2 20 1.00
Suoprofen 1 20 1.80
Nefopam 1 19 0.60
Tiaprofen 2 17 0.51
Zomepirac 2 16 6.40
Oxindanac 1 16 1.30
Sulindac 2 15 0.75
Lornoxicam 1 15 0.80
Bromfenac 1 12 2.10
Fluproquazone 1 12 2.80
Nabumetone 1 10 1.60
Oxaprozin 1 10 2.30
Isoxicam 1 8 1.00
Ticlotil 1 8 2.10
Tenoxicam 1 6 1.20
Flurbiprofen 1 6 1.30
Note that all low dose aspirin was 325 mg/day.Arthritis Research & Therapy    Vol 10 No 1    Moore et al.
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These headline results must be qualified in several ways. Most
importantly, almost 90% of individuals investigated were
healthy, most were young (age <40 years) and most were
men. It is not known whether these results can be extrapolated
to older populations, often with comorbid conditions, using
aspirin or NSAIDs. We found no conclusive evidence that
baseline faecal blood loss, or faecal blood loss with aspirin at
doses above 1,800 mg/day, was higher in patients than in
healthy volunteers.
Other than obvious differences between trials in terms of
drugs and doses tested, the main difference between trials
was in the duration of therapy. We set a minimum limit of 7
days of treatment, in part to limit under-estimation of faecal
blood loss caused by slow intestinal transit time [34]. More
recent studies have tended to include longer treatment dura-
tion and older studies tended to involve shorter treatment
durations, but there was an insufficient number of common
therapies to allow a sensible comparison to be conducted,
especially because the number of patients in each treatment
arm was small. There was the added complication of crosso-
ver trials, with disparate washout periods, although a minimum
of 7 days was imposed as an inclusion criterion.
Additional limitations arose from the apparent differences
between trials in participant inclusion. Although most trials
screened participants for a history of potential for increased
gastrointestinal damage, or drugs that might interfere or con-
found measurements, fewer than one-third excluded partici-
pants with higher blood loss by means of faecal occult blood
screening or measurement. Moreover, only one trial in 10 col-
lected stool samples in controlled conditions from inpatients,
and full description of the methods used to measure stool or
blood radioactivity was uncommon. All of these features indi-
cated that a cautious descriptive analysis of these data was all
that was possible.
Although frank bleeding from the upper and lower gastrointes-
tinal tracts is associated with high levels of anaemia, including
very low haemoglobin levels (<100 g/l) [42], there is no direct
evidence linking anaemia with low-level blood loss into the
bowel, although aspirin, NSAIDs and perhaps coxibs are
known to be associated with varying frequencies of frank gas-
trointestinal bleeding. There is circumstantial evidence that
NSAIDs are linked both to increased faecal blood loss and to
increased anaemia [30]. For low-dose aspirin, which pro-
duced faecal blood loss similar to that of NSAIDs in these tri-
als, a limited body of literature has examined only small
numbers, with one study [43] suggesting an association
between low-dose aspirin use and anaemia and another one
[44] finding no association. A small comparative study of mis-
oprostol and no treatment in 21 patients with small bowel
enteropathy and iron deficiency anaemia showed a rise of 15
g/l in haemoglobin with misoprostol, as compared with no
change without treatment [45].
It is interesting that individual participants could have bleeding
rates that were much higher than the average, more frequently
with full-dose aspirin than with NSAIDs. It is tempting to con-
sider that individuals with daily faecal blood loss of more than
5 ml or 10 ml might be more likely to develop anaemia, espe-
Figure 2
Mean daily faecal blood loss in individual treatment arms Mean daily faecal blood loss in individual treatment arms. Daily faecal 
blood loss is shown on a logarithmic scale for aspirin, cyclo-oxygenase-
2 selective inhibitors (coxibs) and nonsteroidal anti-inflammatory drugs 
(NSAIDs) with more than 20 participants. The size of the symbol is pro-
portional to the number of individuals (inset scale).
Figure 3
Average daily faecal blood loss in individual trials of aspirin according  to daily aspirin dose Average daily faecal blood loss in individual trials of aspirin according 
to daily aspirin dose. The size of the symbol is proportional to the 
number of individuals (inset scale).Available online http://arthritis-research.com/content/10/1/R7
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cially because some individuals had daily blood loss of 50 ml
or more (for example, in the study conducted by Bowne and
coworkers [28]). Caution is needed, however, because in
most cases the information we obtained indicates that high
blood loss was identified over just a few days, and we have no
good evidence about the longer term. The exception [28], a re-
analysis of ibuprofen used in healthy male volunteers, indi-
cated that very high blood loss may occur infrequently and
intermittently. Longer studies and larger numbers would be
needed to demonstrate the cause and effect between daily
faecal blood loss and anaemia.
Anaemia is common in older people living in the community;
13% of a Canadian population of 17,000 had anaemia using
the World Health Organization definition (<120 g/l for women
and <130 g/l for men), and 4% had haemoglobin levels below
110 g/l [46]. Anaemia is also common (prevalence about
50%) in some rheumatological conditions [47]. Of 72,000
older patients admitted to hospital with myocardial infarction,
43% satisfied a World Health Organization definition of anae-
mia [48]. Anaemia in older people is associated with greater
mortality in association with heart failure [49,50], angina [51]
and myocardial infarction, especially with compromised renal
function [52]. Anaemic older patients in hospital are less likely
to resume activities of daily living [53] and anaemia is associ-
ated with poor cognition [54].
Where a cause for anaemia can be found and treated, quality
of life improves. This is the case with blood transfusion in older
people, or when haemoglobin levels rise upon treatment with
erythropoietin in cancer [55] or renal disease. There are no
reliable studies demonstrating improvements in hard clinical
outcomes or mortality.
Conclusion
At baseline, or with placebo, faecal blood loss is generally
measured at 1 ml/day or below. With low-dose aspirin and
some NSAIDs, average values in studies may be two to four
times this, and with anti-inflammatory doses of aspirin there is
consistent evidence for much higher average losses. A small
proportion of individuals respond to aspirin or NSAIDs with
much higher faecal blood loss of above 5 ml/day or above 10
ml/day. Blood loss of 5 ml/day would represent almost 2 l if
continued over a year, a not insubstantial loss, which might be
a consequence of NSAID use in up to one in 20 users. Similar
concerns apply to low-dose aspirin. There are significant limi-
tations regarding the quality and validity of reporting of these
studies, such as limited size and inclusion of inappropriate par-
ticipants. The potential for blood loss and consequent anae-
mia requires more study.
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